AzurRx BioPharma, Inc. researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea. The company was incorporated in 2014 and is headquartered in Brooklyn, New York.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AZRX
CUSIPN/A
Phone646-699-7855
Debt
Debt-to-Equity RatioN/A
Current Ratio0.64
Quick Ratio0.64
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.14 per share
Price / Book18.43
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-11,090,000.00
Net MarginsN/A
Return on Equity-468.72%
Return on Assets-181.43%
Miscellaneous
Employees13
Outstanding Shares16,790,000
Market Cap$44.67
AzurRx BioPharma (NASDAQ:AZRX) Frequently Asked Questions
What is AzurRx BioPharma's stock symbol?
AzurRx BioPharma trades on the NASDAQ under the ticker symbol "AZRX."
How were AzurRx BioPharma's earnings last quarter?
AzurRx BioPharma Inc (NASDAQ:AZRX) posted its quarterly earnings results on Monday, May, 14th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.18) by $0.11. View AzurRx BioPharma's Earnings History.
When is AzurRx BioPharma's next earnings date?
What price target have analysts set for AZRX?
1 analysts have issued 12-month price targets for AzurRx BioPharma's shares. Their forecasts range from $6.00 to $6.00. On average, they expect AzurRx BioPharma's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 132.6% from the stock's current price. View Analyst Ratings for AzurRx BioPharma.
What is the consensus analysts' recommendation for AzurRx BioPharma?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AzurRx BioPharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
Who are some of AzurRx BioPharma's key competitors?
Some companies that are related to AzurRx BioPharma include VERONA PHARMA P/S (VRNA), VBI Vaccines (VBIV), Nature's Sunshine Products Common Stock (NATR), BioXcel Therapeutics (BTAI), NewLink Genetics (NLNK), Innovate Biopharmaceuticals (INNT), Protagonist Therapeutics (PTGX), Tetraphase Pharmaceuticals (TTPH), Newron Pharmaceuticals (NWPHF), Spero Therapeutics (SPRO), BioDelivery Sciences International (BDSI), Calithera Biosciences (CALA), Aldeyra Therapeutics (ALDX), Spring Bank Pharmaceuticals (SBPH) and Eleven Biotherapeutics (EBIO).
Who are AzurRx BioPharma's key executives?
AzurRx BioPharma's management team includes the folowing people:
- Mr. Johan M. Spoor, Pres, CEO & Director (Age 46)
- Mr. Maged S. Shenouda R.Ph, MBA, CFO & Director (Age 54)
- Mr. Daniel Dupret, Chief Scientific Officer (Age 62)
- Dr. Mathieu Schué Ph.D., Head of Laboratory
- Dr. James E. Pennington, Chief Medical Officer (Age 75)
When did AzurRx BioPharma IPO?
(AZRX) raised $15 million in an IPO on Friday, September 9th 2016. The company issued 2,100,000 shares at a price of $6.00-$8.00 per share. WallachBeth Capital and Network 1 Financial Securities served as the underwriters for the IPO.
Has AzurRx BioPharma been receiving favorable news coverage?
Media coverage about AZRX stock has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm scores the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. AzurRx BioPharma earned a news sentiment score of 0.11 on Accern's scale. They also gave news coverage about the company an impact score of 45.43 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
How do I buy shares of AzurRx BioPharma?
Shares of AZRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AzurRx BioPharma's stock price today?
One share of AZRX stock can currently be purchased for approximately $2.58.
How big of a company is AzurRx BioPharma?
AzurRx BioPharma has a market capitalization of $44.67 million. AzurRx BioPharma employs 13 workers across the globe.
How can I contact AzurRx BioPharma?
AzurRx BioPharma's mailing address is 760 PARKSIDE AVENUE SUITE 304, BROOKLYN NY, 11226. The company can be reached via phone at 646-699-7855 or via email at [email protected]
MarketBeat Community Rating for AzurRx BioPharma (NASDAQ AZRX)
MarketBeat's community ratings are surveys of what our community members think about AzurRx BioPharma and other stocks. Vote "Outperform" if you believe AZRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AZRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
